Core Viewpoint - The company will continue to focus on smart healthcare and smart city sectors, driving growth through both internal development and external expansion strategies [2] Group 1 - The company aims to strengthen its core competitiveness in the future [2] - The development path will be supported by a dual approach of internal growth and external expansion [2]

Core Viewpoint - Rongke Technology's stock has shown volatility with a year-to-date increase of 14.94%, but a recent decline of 14.79% over the past 20 days, indicating mixed performance in the market [1][2]. Financial Performance - For the period from January to September 2025, Rongke Technology reported revenue of 454 million yuan, a year-on-year decrease of 4.49%, and a net profit attributable to shareholders of -31.69 million yuan, a significant decline of 378.82% [2]. - The company has cumulatively distributed 99.14 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of October 30, Rongke Technology's stock price was 23.39 yuan per share, with a trading volume of 283 million yuan and a turnover rate of 1.94%, resulting in a total market capitalization of 14.963 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 141 million yuan on August 13, accounting for 15.87% of total trading volume [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 10.80% to 54,000, while the average circulating shares per person increased by 12.10% to 11,834 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest, holding 2.1668 million shares, an increase of 158,900 shares from the previous period [3]. Business Overview - Rongke Technology, established on November 18, 2005, and listed on February 16, 2012, operates in the fields of smart healthcare, health data, and intelligent cloud services, with main business revenue composition being 73.25% from self-developed products and services, 26.64% from system integration, and 0.12% from other sources [1].

Core Viewpoint - The company, Rongke Technology, is focusing on the dual growth strategy of internal growth and external expansion, particularly in the fields of smart healthcare and smart cities [2]. Group 1 - The company aims to strengthen its core competitiveness while pursuing its main business in smart healthcare and smart cities [2]. - Future development directions include both organic growth and potential mergers and acquisitions [2].

Group 1 - The DRG/DIP concept declined by 1.31%, ranking among the top declines in the concept sector, with notable declines in companies like Jiarun Technology, Jiahe Meikang, and ST Yilianzhong [1][2] - Among the DRG/DIP concept stocks, six companies saw price increases, with Madi Technology, Weining Health, and Shanda Diwei leading the gains at 2.98%, 1.29%, and 1.29% respectively [1][2] - The DRG/DIP concept experienced a net outflow of 379 million yuan, with 18 stocks facing net outflows, and Jiarun Technology leading with a net outflow of 135 million yuan [2][3] Group 2 - The top gainers in today's concept sectors included Hainan Free Trade Zone at 4.35%, BC Battery at 3.89%, and Metal Zinc at 3.60%, while several sectors like DRG/DIP and others faced declines [2] - The main stocks with significant net inflows included Madi Technology, Huaping Co., and Shanda Diwei, with net inflows of 19.93 million yuan, 13.24 million yuan, and 8.86 million yuan respectively [2][3] - The stocks with the highest net outflows in the DRG/DIP concept included Jiarun Technology, Dongruan Group, and Donghua Software, with net outflows of 135.44 million yuan, 61.65 million yuan, and 57.21 million yuan respectively [2][3]

Group 1 - The core point of the article is that Rongke Technology (SZ 300290) announced a board meeting to discuss a proposal for a comprehensive credit facility from CITIC Bank [1] - For the first half of 2025, Rongke Technology's revenue composition is as follows: social security and medical services account for 68.26%, government services account for 28.07%, and other industries account for 3.67% [1] - As of the report, Rongke Technology has a market capitalization of 14.4 billion yuan [1] Group 2 - The article also mentions a controversial company promoting the tokenization of real estate overseas, with claims that participants can earn significant returns, which has raised skepticism among some investors [1]

第六届董事会第六次会议决议公告 证券代码：300290 证券简称：荣科科技 公告编号：2025-042 荣科科技股份有限公司 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、荣科科技股份有限公司（以下简称公司）第六届董事会第六次会议的会议通 知于2025年10月21日以电子邮件方式发送给各位董事。 2、本次董事会会议于2025年10月27日以通讯方式召开。 3、本次董事会应出席董事7名，实际出席董事7名，7名董事以通讯方式出席。 4、本次董事会由董事长段刚主持，公司高级管理人员列席了本次会议。 5、本次董事会会议的召集、召开符合《公司法》等有关法律法规和《公司章程》 的相关规定。 二、董事会会议审议情况 与会董事经过认真审议，以表决票方式通过了以下议案： （一）审议通过《荣科科技 2025 年第三季度报告》 根据《创业板股票上市规则》等法律、法规的相关要求，结合本公司 2025 年第 三季度的整体经营管理情况，编制了《2025 年第三季度报告》。 《2025 年第三季度报告》详见中国证监会指定的创业板 ...

Core Points - The company reported third-quarter revenue of 162 million, representing a year-on-year increase of 0.43% [1] - The net profit for the third quarter was a loss of 4.4611 million, a decline of 71.91% [1] - For the first three quarters, the company achieved revenue of 454 million, a year-on-year decrease of 4.49% [1] - The net profit for the first three quarters was a loss of 31.6901 million, a significant decline of 378.82% [1]

Financial Performance - The company's operating revenue for Q3 2025 was ¥162,091,445.29, an increase of 0.43% compared to the same period last year[5] - The net profit attributable to shareholders was -¥4,461,088.68, a decrease of 71.91% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥5,322,317.99, down 27.39% from the previous year[5] - Total operating revenue for the current period was ¥453,708,212.99, a decrease of 4.3% compared to ¥475,017,586.97 in the previous period[21] - The net profit for the current period was a loss of ¥22,667,543.02, compared to a profit of ¥1,258,376.60 in the previous period[22] - Other comprehensive income after tax for the current period was a loss of ¥12,200,673.20, compared to a loss of ¥283,594.39 in the previous period[22] - The total comprehensive income for the current period was a loss of ¥34,868,216.22, compared to a gain of ¥974,782.21 in the previous period[22] - Basic earnings per share (EPS) decreased to -0.0495 from -0.0103 year-over-year[23] Assets and Liabilities - The total assets at the end of Q3 2025 were ¥1,455,754,688.25, a decrease of 4.29% from the end of the previous year[5] - The total assets decreased to ¥1,455,754,688.25 from ¥1,521,037,838.82, reflecting a decline of 4.3%[20] - Total liabilities decreased to ¥608,391,543.72 from ¥623,827,754.67, a reduction of 2.5%[20] - The total equity attributable to shareholders of the parent company was ¥776,073,441.34, down from ¥821,525,594.05, a decrease of 5.5%[20] Cash Flow - Cash flow from operating activities showed a net outflow of -¥160,731,967.50, a decrease of 19.64% year-to-date[5] - Net cash flow from operating activities was -160,731,967.50 CNY, compared to -134,350,918.95 CNY in the previous period[23] - Cash inflow from operating activities totaled 514,796,447.85 CNY, down from 538,015,437.14 CNY[23] - Cash outflow from operating activities increased slightly to 675,528,415.35 CNY from 672,366,356.09 CNY[24] - Net cash flow from investing activities was -11,206,883.02 CNY, an improvement from -31,964,224.77 CNY in the previous period[24] - Cash inflow from financing activities increased to 93,477,846.49 CNY from 62,957,946.31 CNY[24] - Net cash flow from financing activities was 53,437,873.23 CNY, compared to 18,000,765.26 CNY previously[24] - The ending cash and cash equivalents balance was 91,400,511.50 CNY, down from 119,275,557.81 CNY[24] - The company received 284,000,001.00 CNY from investment recoveries, up from 176,000,000.00 CNY[24] Shareholder Information - The total number of common shareholders at the end of the reporting period was 54,042, with no preferred shareholders having restored voting rights[14] - The largest shareholder, Henan Xinchuan Shuchuang Private Equity Investment Fund Partnership, holds 20.01% of the shares, totaling 128,000,000 shares[14] - The company has no preferred shareholders and no changes in the number of restricted shares during the reporting period[16] Inventory and Expenditures - Inventory increased by 32.07% to ¥345,597,358.76, primarily due to increased project inputs during the reporting period[9] - Inventory increased significantly from 261,681,287.95 to 345,597,358.76, indicating a potential buildup of stock[18] - The company reported a significant increase in development expenditures, rising by 203.66% to ¥22,802,394.96, attributed to increased R&D capitalization[9] - Research and development expenses for the current period were ¥51,111,612.21, an increase of 3.1% from ¥49,553,525.40 in the previous period[21] - The company reported a significant increase in short-term borrowings, rising to ¥100,187,196.69 from ¥28,509,509.28, an increase of 251.5%[20] Financial Auditing - The company’s third-quarter financial report was not audited[25]

Core Insights - Rongke Technology experienced a stock decline of 1.53% on October 20, with a trading volume of 475 million yuan [1] - The company reported a financing buy-in of 36.72 million yuan and a financing repayment of 61.74 million yuan on the same day, resulting in a net financing outflow of 25.02 million yuan [1] - As of October 20, the total margin balance for Rongke Technology was 1.282 billion yuan, representing 9.17% of its market capitalization, indicating a high level of financing [1] Financing Summary - On October 20, Rongke Technology had a financing buy-in of 36.72 million yuan, with a total financing balance of 1.282 billion yuan, which is above the 90th percentile of the past year [1] - The margin trading data showed no short selling activity on October 20, with a short selling balance of 0 yuan, indicating a lack of bearish sentiment [1] Company Performance - As of June 30, the number of shareholders for Rongke Technology was 60,600, a decrease of 6.30% from the previous period [2] - The company reported a revenue of 292 million yuan for the first half of 2025, a year-on-year decrease of 7.01%, and a net profit attributable to shareholders of -27.23 million yuan, a significant decline of 576.78% [2] - Since its A-share listing, Rongke Technology has distributed a total of 99.14 million yuan in dividends, with no dividends paid in the last three years [2] Shareholding Structure - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder of Rongke Technology, holding 2.0079 million shares, a decrease of 21,000 shares from the previous period [2]

Core Insights - The conference held by Rongke Technology on October 17, 2025, focused on the theme "Gathering Ecology, Smart Future," showcasing the company's 20-year development journey and future strategic planning [1] - The company aims to deepen cooperation with partners and enhance its position in smart healthcare and smart city sectors while building an open ecological system [1] Company Strategy - Rongke Technology's President Wang Gongxue outlined the company's strategic planning and 2026 channel cooperation policy, emphasizing the accumulation of experience over 20 years, serving over 5,000 medical institutions and more than 80% of the top 100 hospitals [2] - The company has established five major bases across various provinces and is committed to an "innovation-driven development" approach, forming four product systems: smart healthcare, smart platforms, smart health, and smart cities [2] - The company plans to focus on five areas: market, service, digitalization, research and development, and capital, to build a marketing system based on provincial units and a comprehensive service system [2] Industry Trends - Experts discussed the evolution of the smart ecological industry and hospital information systems, highlighting the importance of medical data resources and asset platform systems [3] - The impact of AI on medical paradigms and software evolution was analyzed, with case studies demonstrating deep applications of AI in medical institutions and strategies to address challenges faced by medical AI [3] Product Innovations - Rongke Technology and its subsidiaries launched new products including a medical data governance platform and a high-quality development monitoring system, showcasing advancements in AI applications across various healthcare scenarios [4] - The company aims to provide comprehensive solutions for the digital transformation of the industry by integrating AI, big data, and IoT technologies [4] Partnerships and Recognition - Rongke Technology awarded three partnership awards to outstanding collaborators, emphasizing the importance of cooperation in driving industry digital transformation [4] - The company signed strategic cooperation agreements with over ten well-known industry enterprises to expand its industrial boundaries and enhance ecological cooperation value [4] Future Vision - The Chairman of Rongke expressed gratitude to long-term partners and highlighted the company's commitment to innovation and collaboration in the digital economy [5] - The company aims to continue its journey of growth and cooperation, focusing on creating a prosperous future together with its partners [5]